Actively Recruiting

Age: 18Years - 100Years
All Genders
Healthy Volunteers
ID05336851

Emergency PanorOmic Wide Association Study in Respiratory Infectious Disease (ePWAS-RID)

Led by The University of Hong Kong · Updated on 2026-05-12

2000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting an observational study to develop an emergency PanorOmics Wide Association Study (ePWAS) focused on adult patients with suspected, acute, community-acquired respiratory infectious disease (scaRID) presenting in emergency departments. The study aims to create a biobank of biological samples and perform targeted research to discover new diagnostic, prognostic, and therapeutic markers for respiratory infectious diseases, which include viral, bacterial, fungal, and mixed infections, as well as pneumonia and sepsis. This research builds on previous genomic and molecular studies to better understand host responses and disease mechanisms early in the illness. Participants will provide blood and saliva samples collected mostly within 8 days of symptom onset. Those with viral, bacterial, or co-infections will have one sample taken in the emergency department or hospital, with additional samples collected at approximately 24 and 48 hours after symptom onset if they agree. Control subjects, including healthy individuals and those with low illness scores, may also provide samples on a similar schedule. The biobank will include various liquid biopsy specimens such as whole blood, plasma, serum, and salivary components to analyze multiple biological markers across genomics, proteomics, metabolomics, and other fields. During the study, participants will be monitored for up to 30 days to evaluate clinical progression using the WHO Clinical Progression Scale and mortality outcomes up to one year. Researchers will collect clinical data alongside biological samples to identify patterns that distinguish low-risk from high-risk patients. The study involves informed consent, with assessments including temperature and symptom tracking to confirm eligibility. This ongoing study is sponsored by The University of Hong Kong and will continue to gather data until at least May 2028.

CONDITIONS

Brief Title

Emergency PWAS in Respiratory Infectious Disease

Who Can Participate

Age: 18Years - 100Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years of age or older
  • Suspected acute community-acquired respiratory infectious disease (scaRID)
  • Symptom onset less than 8 days prior
  • Fever or temperature above 37.5°C or related symptoms such as chills, leucocytosis, or altered mental status
  • Presence of respiratory, systemic, or gastrointestinal symptoms without an obvious alternative cause
  • Ability to provide informed consent
  • Control subjects include adults with low National Early Warning Scores and no acute illness
Not Eligible

You will not qualify if you...

  • Refusal to provide consent
  • Hospitalization within the past 28 days
  • Participation in another clinical trial
  • Presence of cellulitis, skin or orthopedic infections
  • Urinary tract infection
  • Acute abdominal sepsis
  • Sexually transmitted diseases
  • HIV infection
  • Immunocompromised status or potential neutropenic fever
  • Solid organ or stem cell transplant within the last 90 days
  • Active graft-versus-host disease or bronchiolitis obliterans
  • Severe travel-related diseases requiring urgent care
  • Stroke
  • Toxidrome
  • Non-organic acute psychosis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Up to 8 days from symptom onset

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) in the emergency department or hospital

Diagnostic Evaluation

Duration - Within 8 days from symptom onset

Participants provide blood and saliva samples for biomarker analysis to identify panorOmic signatures related to respiratory infectious diseases.

At least 1 visit for blood and saliva collection in the emergency department or hospital; additional samples may be collected at 24 hours and 48 hours after symptom onset if participants agree

Long-term Monitoring

Duration - Up to 1 year

Participants are followed for clinical outcomes related to respiratory infectious disease severity and mortality.

Follow-up assessments as needed for up to 30 days and mortality monitoring up to 1 year

Trial Site Locations

Total: 1 location

1

Hong Kong University

Hong Kong, China

Actively Recruiting

Loading map...

Research Team

T

Timothy H Rainer, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

7

Similar Trials

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging t...

Bacterial Infections

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment.

Kathy Leung, Joseph T Wu, Di Liu...

https://pubmed.ncbi.nlm.nih.gov/32277878

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.

Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso...

https://pubmed.ncbi.nlm.nih.gov/32401715